Skip to main content
Glama

Digitalnz

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint, openWorldHint, idempotentHint, and destructiveHint=false, but the description adds substantial behavioral context beyond those hints: it cascades through multiple lookup endpoints, degrades gracefully when GLEIF/OpenFIGI are unavailable, returns unresolved identifiers explicitly, and asserts nothing when multiple matches exist. This level of behavioral disclosure is unusually thorough.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with intuitive example queries and the 'Use FIRST' directive, and every major section serves a purpose. However, it is quite long and contains some dense parentheticals that could be tightened, such as the lengthy explanation of issuer-name ambiguity. It earns a high score for being structured and informative, but not perfect because the length risks burying key instructions.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

There is no output schema, so the description carries the full burden of explaining return values. It does this thoroughly: for companies it lists CIK, ticker, company_name, LEI, FIGI, ownership, and figi_candidates/unresolved fields; for drugs it lists RxCUI, ingredient, brand, and citation. It also covers edge cases like non-US issuers, non-equity instruments, and enrichment failures, making it complete for an agent to call correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the baseline is 3, but the description goes far beyond the schema. It clarifies what 'value' means for each type, gives concrete examples (AAPL, 0000320193, ozempic), and warns against including trailing security-class words for bond lookups. The type enum is also expanded with the exact lookup scope and resolution paths for company and drug.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description uses specific verbs and resources: resolve a user-spoken NAME to canonical/official identifiers, with explicit supported types (company and drug) and the exact identifiers returned (CIK, ticker, LEI, FIGI, RxCUI). It also differentiates itself by stating it should be used FIRST whenever a name is known but an ID is needed, distinguishing it from sibling tools like entity_profile and compare_entities.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'Use FIRST whenever you have a name but need an ID,' which is a clear invocation condition. It also provides type-specific guidance, examples of accepted inputs, and caveats like passing the issuer name exactly instead of the full noun phrase for bonds. This gives an agent actionable direction on when and how to use the tool versus relying on other lookups.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Digitalnz toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation2/5

Several tools are difficult to distinguish: ask_pipeworx and ask_pipeworx_beta are currently identical, and ask_pipeworx_grounded, deep_research, and ask_pipeworx have fuzzy boundaries. The polymarket_* family plus bet_research also overlap heavily, requiring agents to carefully parse long descriptions to avoid misselection.

Naming Consistency4/5

Naming is predominantly snake_case with a verb-first pattern (ask_, search, subscribe, unsubscribe, list_) and clear prefix families like polymarket_ and pipeworx_. Minor deviations like ai_visibility_check and entity_profile use noun-first phrasing, but the overall pattern is still predictable and readable.

Tool Count2/5

33 tools is heavy for any single server, and the count is especially inappropriate given the server is named Digitalnz but only two tools (search, record) serve that domain. The rest form an unrelated grab-bag of data research, prediction-market, AI-visibility, memory, and utility tools.

Completeness3/5

The research workflow is fairly well covered: ask/grounded/deep modes, entity resolution, comparisons, claim validation, subscriptions, and alerts all exist. However, the DigitalNZ surface is nearly absent—just search and record—which is a significant gap for the declared server name, while other domains like AI visibility and npm dependencies are isolated one-offs.

Resources